

A Randomized Phase II Study of Afinitor (RAD001, Everolimus) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma

New Research Opportunity

Research opportunity for patients with metastatic non-clear cell renal-cell carcinoma

ASPEN



ASPEN, a new investigator-initiated study being led by Duke University, is now enrolling patients with metastatic renal-cell carcinoma with non-clear cell histology. Papillary, chromophobe, and undifferentiated tumor types are permitted.

This study seeks to enroll 108 subjects from participating research sites in the U.S., Canada, and U.K. Eligible patients will be randomly assigned to receive either everolimus (Afinitor) or sunitinib (Sutent) as treatment for their cancer. This study will compare the anti-tumor activity of everolimus vs. sunitinib in this population.

- Patients (and their doctors) will know which drug they will be taking
- Both drugs are oral cancer agents
- Study treatments will be provided to the participants at no charge
- Subjects may continue receiving study drugs until disease progression, unacceptable toxicities, or withdrawal of consent

To learn more about participating in this research study, please contact your local ASPEN coordinator. To locate a participating site and ASPEN coordinator, visit clinicaltrials.gov and search for study NCT01108445.

ASPEN STUDY COORDINATOR

Name:

Contact Information:



PRO00020714